Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck organon & Co. — Research and Development (R&D) ($M) ($M)
Organon & Co. Form 10-Q / 10-K
Latest, FY2021
443
Period ended Dec 31, 2021
Change on a year earlier
+111.0%
210 in FY2020
History
3 years
Since FY2019
Sources
1
Organon & Co. SEC Filing (0001821825-22-000002)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Organon & Co. — Research and Development (R&D) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2021 | Dec 31, 2021 | 443 | +111.0% | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
| FY2020 | Dec 31, 2020 | 210 | -4.5% | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
| FY2019 | Dec 31, 2019 | 220 | – | Organon & Co. SEC Filing (0001821825-22-000002) ↗ |
Cite this data
StockData. (2026). Merck Organon & Co. — Research and Development (R&D) ($M) ($M), annual FY2019–FY2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn_rd
See every metric in the Merck KPI table. Data updated Oct 26, 2026.